Financial Data and Key Metrics Changes - Operating expenses increased to $7.9 million from $4.5 million in the previous year, primarily due to the introduction of the biopharma business and increased headcount [13] - Cash and cash equivalents rose to $12.6 million compared to $2 million at the end of the previous year [14] - Loss from discontinued operations decreased from $1.2 million to $900,000 [13] Business Line Data and Key Metrics Changes - The company transitioned from the consumer device market to focus on biopharmaceuticals, specifically immunotherapy, marking a strategic pivot [12][3] - The ClearUP device business was discontinued, and non-core neuromodulation programs were suspended to concentrate resources on high-value biotherapeutic opportunities [4] Market Data and Key Metrics Changes - The oncology supportive care market is valued at approximately $15 billion and is expected to grow to $20 billion by the 2030s, with significant unmet needs for next-generation protective agents [6] - Entolimod is positioned to disrupt established markets due to its unique properties that prevent programmed cell death in vital tissues [7] Company Strategy and Development Direction - The company aims to evolve into a high-impact immunotherapy organization, focusing on the TLR5 platform and its lead candidate, Entolimod [3] - The acquisition of Velocity Bioworks allows for internal manufacturing capabilities, reducing development timelines and costs while ensuring control over the supply chain [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of national preparedness and the demand for domestic biomanufacturing as key macro trends [10] - The company is committed to executing its vision and is optimistic about capturing immediate opportunities in national preparedness while driving long-term value in oncology supportive care markets [17] Other Important Information - The company acquired assets from Scorpius Holdings, Inc for $16.3 million, financed through a senior secured convertible note [14] - A common stock purchase agreement allows the company to raise up to $50 million under certain conditions over the next two years [15] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.

Tivic Health Systems (NasdaqCM:TIVC) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsLisa Wolf - CFOMichael Handley - CEOOperatorWelcome to Tivic's conference call to discuss fiscal year and fourth quarter 2025 financial results. This call has been pre-recorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, please note that during today's call, management will make various forward-looking statem ...

Financial Data and Key Metrics Changes - Operating expenses increased to $7.9 million in 2025 from $4.5 million in 2024, primarily due to the introduction of the biopharma business and increased headcount [12][13] - Cash and cash equivalents rose to $12.6 million at the end of 2025, compared to $2 million at the end of 2024 [14] - Loss from discontinued operations decreased from $1.2 million to $900,000 for the year ended December 31, 2025 [13] Business Line Data and Key Metrics Changes - The company transitioned from a consumer device business to a focused immunotherapy biopharmaceutical company, discontinuing the ClearUP device business and non-core neuromodulation programs [4][12] - The acquisition of Velocity Bioworks is expected to reduce development timelines and costs for Entolimod, while also serving as a revenue driver [9][10] Market Data and Key Metrics Changes - The oncology supportive care market is valued at approximately $15 billion and is expected to grow to $20 billion by the 2030s, with significant unmet needs for next-generation protective agents [6] - Entolimod is positioned to disrupt established markets due to its unique properties that prevent programmed cell death in vital tissues [6] Company Strategy and Development Direction - The company aims to evolve into a high-impact immunotherapy organization, focusing on the TLR5 platform and its lead candidate, Entolimod [3][4] - The strategy includes securing government partnerships and funding for Entolimod, particularly for its use in biodefense against acute radiation syndrome [9][10] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2025 marked a fundamental transformation for the company, establishing a robust foundation for growth and value creation [17] - The company is committed to executing its vision and looks forward to providing updates as it reaches upcoming milestones [17] Other Important Information - The company is actively engaged with U.S. government agencies to secure funding and support for Entolimod's development [9] - The acquisition of Scorpius Holdings, Inc. for $16.3 million was financed through a senior secured convertible note [14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Core Insights - Tivic Health is transitioning to a biopharmaceutical company focused on the development of Entolimod™ and its TLR5 platform, including a second-generation molecule, Entolasta [3][4] - The company has decided to discontinue commercial sales of the ClearUP sinus device and suspend development of the non-invasive vagus nerve stimulation platform to concentrate resources on biotherapeutic programs [3] - Tivic is targeting the multi-billion-dollar oncology market, with Entolimod showing potential in preventing cell death in cancer patients, particularly addressing conditions like neutropenia and radiation-induced mucosal necrosis [4] Strategic Focus - The collaboration with the Biomedical Advanced Research and Development Authority (BARDA) is a key part of the corporate strategy, aiming to secure funding for Entolimod as a medical countermeasure for Acute Radiation Syndrome (ARS) [5] - The company is also engaging with allied governments for independent stockpiling of Entolimod for national preparedness [5] Operational Excellence - Tivic has achieved a 200-fold manufacturing scale-up of Entolimod through its subsidiary, Velocity Bioworks, which operates as a Contract Development & Manufacturing Organization (CDMO) [6][12] - This vertical integration allows Tivic to control its domestic supply chain, which is crucial for U.S. government procurement [6] Future Outlook - The company is positioned at the intersection of national preparedness needs, domestic biomanufacturing demand, and investor interest in scalable, high-value assets [7] - Tivic aims to combine late-stage therapeutics with in-house manufacturing to create a profit center that serves both its internal pipeline and the broader biotech industry [8]

Tivic Health Systems Conference Call Summary Company Overview - **Company**: Tivic Health Systems (NasdaqCM:TIVC) - **Industry**: Biopharmaceuticals, specifically focusing on immunotherapeutics and contract development and manufacturing organization (CDMO) services Key Points and Arguments Transformation and Strategic Shift - In 2025, Tivic transitioned from a consumer health tech company to a late-stage, vertically integrated immunotherapeutics company, culminating in the acquisition of manufacturing and development assets in December 2025 [3][4] - The new subsidiary, Velocity Bioworks, was established to support both Tivic and third-party customers, marking a significant transformation for the company [3][8] Acquisition Details - Tivic acquired cGMP manufacturing and development assets from Scorpius Holdings for approximately $16 million, significantly lower than the estimated $30 million-$32 million for outsourcing [6][9] - The acquisition allows Tivic to produce tens of millions of doses of Entolimod annually, enhancing its operational capabilities [7][10] Financial Implications - The acquisition is expected to generate substantial cost savings, estimated at around $10 million before filing a biologics application, with potential for greater savings across the product lifecycle [23][24] - Velocity Bioworks is projected to generate up to $70 million in annual revenue at full capacity, serving 15-20 concurrent client programs [15][19] Market Opportunities - The biologic CDMO market is projected to reach approximately $145 billion by 2037, with a compound growth rate of over 15% [13] - The phase one and phase two segment is growing even faster at 17%-19% annually, driven by over 1,200 biotechnology companies advancing biologics through early clinical development [13][14] Product Development and Regulatory Strategy - Tivic is advancing its TLR5 agonist program with Entolimod, aiming for pivotal regulatory milestones and establishing a strong position with government agencies [11][12] - The company is preparing for a meeting with BARDA to discuss Entolimod as a radiation countermeasure, which is critical for securing government funding [28] Future Outlook - The company anticipates significant revenue generation opportunities through both Entolimod and Velocity Bioworks, with a focus on accelerating clinical and product development timelines [29] - The transformation has positioned Tivic Health to create shareholder value through its proprietary TLR5 platform and secured manufacturing capabilities [29][30] Additional Important Information - The aging population and increasing prevalence of chronic diseases are driving pharmaceutical demand growth, with the number of people aged 65 and older expected to double by 2050 [17] - The facility at Velocity Bioworks is designed to meet government security requirements, enhancing Tivic's likelihood of securing customer funding from U.S. government agencies [25][12] This summary encapsulates the critical insights from the conference call, highlighting Tivic Health Systems' strategic transformation, market opportunities, and future growth potential.

Core Insights - Tivic Health Systems, Inc. will present at the 3rd Annual DealFlow Discovery Conference, focusing on updates regarding its lead drug candidate, Entolimod, and its commercialization strategy [2][3]. Company Updates - The presentation will cover key milestones such as the successful scale-up of Entolimod manufacturing and progress towards cGMP manufacturing for a Biologics License Application (BLA) submission to the FDA [3]. - The strategic integration of Velocity Bioworks, a contract development and manufacturing organization (CDMO), is expected to enhance commercial readiness [3][12]. - Outcomes from a recent TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA) will also be discussed [3]. Product Information - Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist aimed at treating Acute Radiation Syndrome (ARS), showing promising results in animal trials, including improved survival rates and gastrointestinal recovery [10][11]. - The drug is in late-stage development, with additional applications being explored for conditions like Neutropenia and lymphocyte exhaustion [11]. Conference Details - The DealFlow Discovery Conference is a significant event for connecting high-growth companies with the investment community, featuring presentations, networking, and opportunities for capital raising [4][5]. - The conference will take place on January 28-29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, NJ [7].

Core Insights - Tivic Health Systems, Inc. is set to provide a corporate update on its immunotherapeutic candidate Entolimod during the Emerging Growth Virtual Conference on January 21-22, 2026, highlighting recent advancements in manufacturing readiness [1][2] Company Developments - The CEO, Jennifer Ernst, will discuss the scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks, which enhances in-house manufacturing capabilities and introduces new revenue streams [1] - The acquisition of Velocity Bioworks is expected to lower production costs, eliminate outsourcing delays, and accelerate the validation of current Good Manufacturing Practice (cGMP) for Entolimod [1] Product Information - Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that activates the NF-kappaB pathway, showing promising results in animal trials for Acute Radiation Syndrome (ARS), including improved survival rates and gastrointestinal recovery [5][6] - The drug is in late-stage development and aims to prevent cell death in bone marrow and epithelial tissues affected by radiation and age [6] Conference Details - The Emerging Growth Virtual Conference serves as a platform for public companies to present their innovations and major announcements to a broad audience of investors and analysts [3][4]

Tivic Health Systems Conference Summary Company Overview - **Company**: Tivic Health Systems (NasdaqCM:TIVC) - **Focus**: Development of non-invasive medical devices targeting neural pathways and a strong late-stage pipeline in biopharmaceuticals, particularly in immunomodulation and cancer therapeutics [1][2] Key Points Transformation and Pipeline Development - Tivic Health has undergone a significant transformation by acquiring newly licensed assets, leading to a robust late-stage portfolio in biopharmaceuticals [2] - The company maintains a clean capital structure with no debt and anticipates significant value inflection points in the near future [2] Biopharmaceutical Focus - The company is focusing on immunomodulation, utilizing the immune system to combat diseases and improve health outcomes [3] - A biologic licensing agreement was established, including a phase three recombinant protein funded by BARDA for radiation countermeasures, with potential applications in cancer [3][4] Entolimod and Market Opportunities - **Entolimod**: A TLR5 agonist with dual capabilities to treat acute radiation syndrome and cancer-related conditions, showing a 300% increase in survival rates with a single dose [9][23] - The market for GCSF drugs, which Entolimod aims to compete against, is valued at approximately $7.2 billion in 2023, with a broader neutropenia market of around $20 billion [9][31] - Entolimod is positioned as a military countermeasure for nuclear disasters, with a potential market opportunity of $5.2 billion for stockpiling [9][10] Clinical and Regulatory Progress - The company has made significant strides in customer engagement and manufacturing agreements, moving towards a Biologics License Application (BLA) filing [5][10] - The FDA has granted fast track and orphan drug designations for Entolimod, facilitating expedited regulatory processes [11] Future Directions and Strategic Focus - The company plans to focus on Entolimod over the next 6 to 18 months while also exploring other high-potential areas, including cancer therapeutics and vagus nerve stimulation technologies [17][35] - By 2026, Tivic Health aims to have GMP materials ready, FDA meetings completed, and customer interest solidified [34] Additional Insights - The company operates with a capital-light model and has a strong team with extensive experience in drug launches and biopharmaceutical development [16][25] - There is potential for partnerships with larger organizations to scale production and market reach effectively [29] - The vagus nerve technology remains a promising area for future development, with established research backing its efficacy [13][12] Conclusion Tivic Health Systems is positioned for growth with its innovative biopharmaceutical pipeline, particularly through Entolimod, which addresses significant market needs in radiation countermeasures and cancer therapeutics. The company's strategic focus on regulatory pathways and partnerships will be crucial for its success in the coming years.